Sign Out
PDE-5 Inhibitors: Concomitant use of Vericiguat (Verquvo) and PDE-5 inhibitors, such as sildenafil, has not been studied in patients with heart failure and is therefore not recommended due to the potential increased risk for symptomatic hypotension [see Symptomatic Hypotension under Precautions, Pharmacology: Drug Interaction Studies under Actions].
Other Soluble Guanylate Cyclase Stimulators: Vericiguat (Verquvo) is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators, such as riociguat [see Contraindications].
Continue with Google